SCHEMBL7356709

SCHEMBL7356709

Cc1nccnc1CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29607151 1.00
SCHEMBL5306179 0.80 CYP2D6 (0.32)
SCHEMBL30803975 0.80 CYP2D6 (0.32)
SCHEMBL5903240 0.80 ALDH1A1 (0.52)
SCHEMBL10836044 0.78 CYP2D6 (0.35)
SCHEMBL108460 0.76
SCHEMBL29512257 0.76
SCHEMBL230823 0.75 P2RX7 (0.33)
SCHEMBL12925942 0.75 MAOA (0.36)
SCHEMBL5300518 0.75 KDM4E (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165300-A1 METHOD OF EXTRACTING VOLATILE COMPOUNDS FROM TOBACCO MATERIAL BRITISH AMERICAN TOBACCO (INVESTMENTS) LIMITED (GB) 2023-06-01 US claimed
US-20220117970-A1 ARYLQUINAZOLINES MERCK PATENT GMBH (DE) 2022-04-21 US claimed
US-20200187551-A1 METHOD SOUZA CRUZ LTDA. (BR) 2020-06-18 US claimed
EP-3614868-A1 METHOD British American Tobacco (Investments) Limited (GB) 2020-03-04 EP claimed
WO-2018197879-A1 METHOD BRITISH AMERICAN TOBACCO (INVESTMENTS) LIMITED (GB) 2018-11-01 WO claimed
EP-4616913-A2 GCN2 INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2025-09-17 EP disclosed
EP-3746075-B1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-09-03 EP disclosed
EP-4587014-A2 C5AR1 ANTAGONISTS AND USES THEREOF Vanqua Bio, Inc. (US) 2025-07-23 EP disclosed
CN-118119707-A Use of inhibitors to increase CRISPR/Cas insertion efficiency 阿斯利康(瑞典)有限公司 2024-05-31 CN disclosed
CN-118005640-A GCN2 inhibitors and uses thereof 默克专利股份有限公司 2024-05-10 CN disclosed
WO-2024059096-A2 C5AR1 ANTAGONISTS AND USES THEREOF VANQUA BIO, INC. (US) 2024-03-21 WO disclosed
WO-2024059096-A2 C5AR1 ANTAGONISTS AND USES THEREOF VANQUA BIO, INC. (US) 2024-03-21 WO disclosed
EP-2994467-A1 ARYLQUINAZOLINES Merck Patent GmbH (DE) 2016-03-16 EP disclosed
WO-2014183850-A1 ARYLQUINAZOLINES MERCK PATENT GMBH (DE) 2014-11-20 WO disclosed
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-08-13 US disclosed
EP-1200439-A1 1,2-DIHYDRO-1-OXO-PARAZINO(1,2-A) INDOLE DERIVATIVES Novuspharma S.p.A. (IT) 2002-05-02 EP disclosed
WO-2001009136-A1 1,2-DIHYDRO-1-OXO-PYRAZINO[1,2-A]INDOLE DERIVATIVES NOVUSPHARMA S.P.A. (IT) 2001-02-08 WO disclosed
US-5726172-A BENZOXAZINONE DERIVATIVES; TREATMENT OF PRETERM LABOR, DYSMENORRHEA MERCK & CO., INC. (US) 1998-03-10 US disclosed
WO-1997025992-A1 TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-07-24 WO disclosed